candesartan cilexetil has been researched along with Body Weight in 29 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the preventive effect of regression of left ventricular hypertrophy (LVH) on sudden cardiac death (SCD), the incidence of ventricular tachycardia or ventricular fibrillation (VT/Vf) after left coronary artery occlusion in Langendorff preparations was studied in the following five groups: (1) spontaneously hypertensive rats (SHR) without treatment (SHR-N), (2) SHR treated with captopril (SHR-C), (3) SHR treated with the angiotensin II receptor antagonist TCV-116 (SHR-A), (4) SHR treated with hydralazine (SHR-H), and (5) Wistar-Kyoto (WKY) rats." | 7.69 | Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. ( Kanno, M; Kitabatake, A; Kohya, T; Nakaya, H; Saito, H; Tohse, N; Yokoshiki, H, 1995) |
| " We investigated the effect of a new angiotensin II type 1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-([2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl)-1H-benz imi dazole-7- carboxylate (TCV-116), in an animal model of viral myocarditis induced by encephalomyocarditis virus." | 7.69 | An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. ( Matsumori, A; Sasayama, S; Tanaka, A; Wang, W, 1994) |
| "To determine whether angiotensin II participates in the pathogenesis of cardiac hypertrophy and impairs coronary circulation in DOCA/salt hypertension, DOCA hypertensive rats were treated with candesartan cilexetil for 8 wk." | 7.69 | Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure. ( Fujita, H; Itoh, H; Kawa, T; Miki, S; Morimoto, S; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| "These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor." | 5.30 | Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. ( Ikeda, J; Miura, S; Nawata, J; Ohno, I; Shirato, K; Suzuki, J, 1999) |
| "This study was to determine whether combination of the angiotensin II AT1 receptor blocker (ARB), candesartan cilexetil, and exercise training can prevent the development of high-fat diet-induced insulin resistance." | 3.78 | Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet. ( Chen, T; Jiang, H; Koike, T; Li, P; Mu, L; Natsume, Y; Oshida, Y; Wang, Z, 2012) |
| "To evaluate the preventive effect of regression of left ventricular hypertrophy (LVH) on sudden cardiac death (SCD), the incidence of ventricular tachycardia or ventricular fibrillation (VT/Vf) after left coronary artery occlusion in Langendorff preparations was studied in the following five groups: (1) spontaneously hypertensive rats (SHR) without treatment (SHR-N), (2) SHR treated with captopril (SHR-C), (3) SHR treated with the angiotensin II receptor antagonist TCV-116 (SHR-A), (4) SHR treated with hydralazine (SHR-H), and (5) Wistar-Kyoto (WKY) rats." | 3.69 | Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. ( Kanno, M; Kitabatake, A; Kohya, T; Nakaya, H; Saito, H; Tohse, N; Yokoshiki, H, 1995) |
| " We investigated the effect of a new angiotensin II type 1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-([2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl)-1H-benz imi dazole-7- carboxylate (TCV-116), in an animal model of viral myocarditis induced by encephalomyocarditis virus." | 3.69 | An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. ( Matsumori, A; Sasayama, S; Tanaka, A; Wang, W, 1994) |
| "To investigate the role of the renin-angiotensin system (RAS) on nephrosclerosis in salt-loaded, partially nephrectomized spontaneously hypertensive rats (SHR), we evaluated the effects of angiotensin II (ANGII) blockade on the progression of nephrosclerosis with an angiotensin type 1 receptor (AT1rec) antagonist [TCV-116 (TCV)] and an angiotensin-converting enzyme (ACE) inhibitor (enalapril) at the doses equivalent in reducing systemic blood pressure (BP)." | 3.69 | Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. ( Ikenaga, H; Kanno, Y; Okada, H; Saruta, T; Suzuki, H, 1995) |
| "To determine whether angiotensin II participates in the pathogenesis of cardiac hypertrophy and impairs coronary circulation in DOCA/salt hypertension, DOCA hypertensive rats were treated with candesartan cilexetil for 8 wk." | 3.69 | Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure. ( Fujita, H; Itoh, H; Kawa, T; Miki, S; Morimoto, S; Nakagawa, M; Nakata, T; Sasaki, S; Takeda, K; Uchida, A, 1997) |
| "When candesartan cilexetil was administered to Bio TO2 hamsters, cardiac chymase-like activity increased significantly, whereas cardiac fibrosis decreased significantly." | 1.33 | Effect of Angiotensin II Type 1 receptor blocker on cardiac angiotensin-converting enzyme and chymase-like activities, and cardiac fibrosis in cardiomyopathic hamsters. ( Orito, K; Shimamura, S; Shimizu, M; Tanaka, R; Uchida, M; Yamane, Y, 2006) |
| "Treatment with imidapril significantly prevented the L-NAME-induced increase in the gene expression and immunoreactivity of PAI-1, but candesartan cilexetil showed no such effect." | 1.31 | Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts. ( Egashira, K; Katoh, M; Mitsui, T; Narita, H; Takeshita, A, 2000) |
| "A high incidence of maternal toxicity in rabbits characterized by uremia and death was observed when TCV-116, a novel angiotensin II subtype-1 (AT1) receptor antagonist, was orally administered to pregnant rabbits at dosage levels of 3 mg/kg/day or more." | 1.30 | Characterization of the high sensitivity of rabbits to the effects of TCV-116, an angiotensin II receptor antagonist. ( Chatani, F; Ito, K; Kito, G; Sato, K, 1997) |
| "Vascular hypertrophy is considered to be an adaptive response to increased arterial wall stress in hypertension." | 1.30 | Effect of angiotensin II receptor antagonism on vascular hypertrophy and aortic impedance in abdominal aortic-banded rat. ( Kobayashi, S; Kohno, M; Konishi, M; Matsuzaki, M; Obayashi, M; Ohkusa, T; Yamamoto, T; Yano, M, 1999) |
| "These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor." | 1.30 | Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. ( Ikeda, J; Miura, S; Nawata, J; Ohno, I; Shirato, K; Suzuki, J, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (44.83) | 18.2507 |
| 2000's | 15 (51.72) | 29.6817 |
| 2010's | 1 (3.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shweta, A | 1 |
| Cullen-McEwen, LA | 1 |
| Kett, MM | 2 |
| Evans, RG | 1 |
| Denton, KM | 1 |
| Fitzgerald, SM | 1 |
| Anderson, WP | 2 |
| Bertram, JF | 2 |
| Wang, Z | 1 |
| Koike, T | 1 |
| Li, P | 1 |
| Jiang, H | 1 |
| Natsume, Y | 1 |
| Mu, L | 1 |
| Chen, T | 1 |
| Oshida, Y | 1 |
| Mukawa, H | 1 |
| Toki, Y | 1 |
| Miyazaki, Y | 1 |
| Matsui, H | 1 |
| Okumura, K | 1 |
| Ito, T | 1 |
| Saupe, KW | 1 |
| Sobol, SC | 1 |
| Koh, SG | 1 |
| Apstein, CS | 1 |
| Lu, Q | 1 |
| Zhu, YZ | 1 |
| Wong, PT | 1 |
| Nakamura, H | 1 |
| Inoue, T | 1 |
| Arakawa, N | 1 |
| Shimizu, Y | 1 |
| Yoshigae, Y | 1 |
| Fujimori, I | 1 |
| Shimakawa, E | 1 |
| Toyoshi, T | 1 |
| Yokoyama, T | 1 |
| Shimizu, M | 1 |
| Tanaka, R | 1 |
| Uchida, M | 1 |
| Orito, K | 1 |
| Shimamura, S | 1 |
| Yamane, Y | 1 |
| Zorad, S | 1 |
| Dou, JT | 1 |
| Benicky, J | 1 |
| Hutanu, D | 1 |
| Tybitanclova, K | 1 |
| Zhou, J | 1 |
| Saavedra, JM | 1 |
| Kohya, T | 1 |
| Yokoshiki, H | 1 |
| Tohse, N | 1 |
| Kanno, M | 1 |
| Nakaya, H | 1 |
| Saito, H | 1 |
| Kitabatake, A | 1 |
| Nio, Y | 2 |
| Matsubara, H | 2 |
| Murasawa, S | 2 |
| Kanasaki, M | 1 |
| Inada, M | 2 |
| Tanaka, A | 1 |
| Matsumori, A | 1 |
| Wang, W | 1 |
| Sasayama, S | 1 |
| Okada, H | 1 |
| Suzuki, H | 1 |
| Kanno, Y | 1 |
| Ikenaga, H | 1 |
| Saruta, T | 1 |
| Sugimoto, K | 1 |
| Gotoh, E | 1 |
| Takasaki, I | 1 |
| Ebina, T | 1 |
| Iwamoto, T | 1 |
| Takizawa, T | 1 |
| Shionoiri, H | 1 |
| Ishii, M | 1 |
| Kijima, K | 1 |
| Maruyama, K | 1 |
| Mori, Y | 2 |
| Sato, K | 1 |
| Chatani, F | 1 |
| Ito, K | 1 |
| Kito, G | 1 |
| Fujita, H | 1 |
| Takeda, K | 1 |
| Miki, S | 1 |
| Morimoto, S | 1 |
| Kawa, T | 1 |
| Uchida, A | 1 |
| Itoh, H | 1 |
| Nakata, T | 1 |
| Sasaki, S | 1 |
| Nakagawa, M | 1 |
| Otsuka, F | 2 |
| Yamauchi, T | 2 |
| Kataoka, H | 2 |
| Mimura, Y | 2 |
| Ogura, T | 2 |
| Makino, H | 2 |
| Casellas, D | 1 |
| Benahmed, S | 1 |
| Artuso, A | 1 |
| Jover, B | 1 |
| Obayashi, M | 1 |
| Yano, M | 1 |
| Kohno, M | 1 |
| Kobayashi, S | 1 |
| Yamamoto, T | 1 |
| Ohkusa, T | 1 |
| Konishi, M | 1 |
| Matsuzaki, M | 1 |
| Suzuki, J | 1 |
| Ohno, I | 1 |
| Nawata, J | 1 |
| Miura, S | 1 |
| Ikeda, J | 1 |
| Shirato, K | 1 |
| Higashi, T | 1 |
| Kobayashi, N | 3 |
| Hara, K | 3 |
| Shirataki, H | 1 |
| Matsuoka, H | 3 |
| Katoh, M | 1 |
| Egashira, K | 1 |
| Mitsui, T | 1 |
| Takeshita, A | 1 |
| Narita, H | 1 |
| Kishida, M | 1 |
| Takahashi, M | 1 |
| Nakano, S | 1 |
| Tsubokou, Y | 2 |
| Watanabe, S | 1 |
| Campbell, M | 1 |
| Sonkodi, S | 1 |
| Soucek, M | 1 |
| Wiecek, A | 1 |
| Matsuo, T | 1 |
| Ishikawa, E | 1 |
| Ohta, M | 1 |
| Shibouta, Y | 1 |
| Ishimura, Y | 1 |
| Imura, Y | 1 |
| Sugiyama, Y | 1 |
| Alcorn, D | 1 |
| Naruse, M | 1 |
| Tanabe, A | 1 |
| Sato, A | 1 |
| Takagi, S | 1 |
| Tsuchiya, K | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for candesartan cilexetil and Body Weight
| Article | Year |
|---|---|
A candesartan cilexetil/hydrochlorothiazide combination tablet provides effective blood pressure control in hypertensive patients inadequately controlled on monotherapy.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weigh | 2001 |
28 other studies available for candesartan cilexetil and Body Weight
| Article | Year |
|---|---|
Glomerular surface area is normalized in mice born with a nephron deficit: no role for AT1 receptors.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2009 |
Effects of angiotensin II AT1 receptor inhibition and exercise training on insulin action in rats on high-fat diet.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2012 |
Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Abdominal; Benzimidazoles | 2003 |
Effects of AT1 receptor block begun late in life on normal cardiac aging in rats.
Topics: Adenosine; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compoun | 2003 |
Angiotensin receptor gene expression in candesartan mediated neuroprotection.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Com | 2004 |
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compoun | 2005 |
Effect of Angiotensin II Type 1 receptor blocker on cardiac angiotensin-converting enzyme and chymase-like activities, and cardiac fibrosis in cardiomyopathic hamsters.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; C | 2006 |
Long-term angiotensin II AT1 receptor inhibition produces adipose tissue hypotrophy accompanied by increased expression of adiponectin and PPARgamma.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimida | 2006 |
Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Body Weight; Capt | 1995 |
Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction.
Topics: Angiotensin Receptor Antagonists; Animals; Base Sequence; Benzimidazoles; Biphenyl Compounds; Blood | 1995 |
An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Body | 1994 |
Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1995 |
AT1 receptor antagonist, TCV 116, does not prevent cardiac hypertrophy in salt-loaded Dahl salt-sensitive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1996 |
Regulation of gene transcription of angiotensin II receptor subtypes in the heart.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body | 1996 |
Characterization of the high sensitivity of rabbits to the effects of TCV-116, an angiotensin II receptor antagonist.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; | 1997 |
Chronic angiotensin blockade with candesartan cilexetil in DOCA/salt hypertensive rats reduces cardiac hypertrophy and coronary resistance without affecting blood pressure.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body | 1997 |
Effects of chronic inhibition of ACE and AT1 receptors on glomerular injury in dahl salt-sensitive rats.
Topics: Acetylglucosaminidase; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; A | 1998 |
Candesartan and progression of preglomerular lesions in N(G)-nitro-L-arginine methyl ester hypertensive rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Bip | 1999 |
Effect of angiotensin II receptor antagonism on vascular hypertrophy and aortic impedance in abdominal aortic-banded rat.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta, Abdominal; Benzimidazoles | 1999 |
Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzim | 1999 |
Effects of angiotensin II type 1 receptor antagonist on nitric oxide synthase expression and myocardial remodeling in Goldblatt hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Western; Bo | 2000 |
Differential effects of imidapril and candesartan cilexetil on plasminogen activator inhibitor-1 expression induced by prolonged inhibition of nitric oxide synthesis in rat hearts.
Topics: Actins; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyp | 2000 |
Differential effect of chronic inhibition of calcium channel and angiotensin II type 1-receptor on aldosterone synthesis in spontaneously hypertensive rats.
Topics: Adrenal Cortex; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive | 2000 |
Effects of TCV-116 on endothelin-1 and PDGF A-chain expression in angiotensin II-induced hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2001 |
Effects of quinapril on expression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Renal protective effect of candesartan cilexetil in spontaneously hypercholesterolemic rats.
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Be | 2002 |
Glomerular dimensions in spontaneously hypertensive rats: effects of AT1 antagonism.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1996 |
Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats.
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; | 2002 |